Taysha Gene Therapies, Inc. Payments of Debt Issuance Costs
Taysha Gene Therapies, Inc. (TSHA) reported Payments of Debt Issuance Costs of $18.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtIssuanceCosts · last filed 2026-03-19
- Taysha Gene Therapies, Inc. payments of debt issuance costs for the quarter ending 2024-12-31 was $0.00.
- Taysha Gene Therapies, Inc. payments of debt issuance costs for the quarter ending 2024-09-30 was $0.00.
- Taysha Gene Therapies, Inc. payments of debt issuance costs for the quarter ending 2024-06-30 was $0.00.
- Taysha Gene Therapies, Inc. payments of debt issuance costs for the quarter ending 2024-03-31 was $18.00K.
- Taysha Gene Therapies, Inc. payments of debt issuance costs for fiscal 2024 was $18.00K, a 95.49% decline from fiscal 2023.
- Taysha Gene Therapies, Inc. payments of debt issuance costs for fiscal 2023 was $399.00K.
| Period end | Payments of Debt Issuance Costs 3 month | Payments of Debt Issuance Costs 6 month | Payments of Debt Issuance Costs 9 month | Payments of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $0.00 derived: sum of 2 quarters · filed 2026-03-19 | $0.00 derived: sum of 3 quarters · filed 2026-03-19 | $18.00K 10-K · filed 2026-03-19 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $0.00 derived: sum of 2 quarters · filed 2025-11-04 | $18.00K 10-Q · filed 2025-11-04 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $18.00K 10-Q · filed 2025-08-12 | ||
| 2024-03-31 | $18.00K 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | $399.00K 10-K · filed 2025-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |